2024/04/09 by Ajala, Olusegun, Makinde, Adeola, Ogah, Comfort
#Alpha glucosidase inhibition #Saccharomyces cerevisiae #Terminalia catappa #Type 2 Diabetes Mellitu
paper · doi:10.60787/nijophasr-v11-i4-496
Background: Paucity of clinically applicable inhibitors has limited alpha glucosidase inhibition therapeutic strategy of type 2 diabetes management. The current investigation was aimed at evaluating the anti-diabetic alpha glucosidase inhibitory potentials of Terminalia catappa stem bark extract and its fractions, modeling the implicated intestinal brush border membrane alpha glucosidases with the baker’s yeast alpha glucosidase maltase. Methods: A crude stem bark extract of Terminalia catappa and its n-hexane-, dichloromethane- and methanol-soluble fractions were incubated with the baker’s yeast alpha glucosidase at various final assay mixture concentrations, carrying along acarbose as reference standard. IC50 values were calculated from % inhibition vs concentration plots and analyzed using one-way ANOVA with Tukey’s post hoc comparison. Results: The methanol, n-hexane and dichloromethane fractions inhibited alpha glucosidase with IC50 values 173.85 ± 6.90 ?g/ml, 258.56 ± 12.90 ?g/ml and 329.90 ± 10.67 ?g/ml respectively which are in the same order as that of acarbose (123.26 ± 15.56 ?g/ml) and significantly smaller (p < 0.0001) than that of the crude extract (527.67 ± 16.32 ?g/ml). Conclusion: The three fractions potently inhibited baker’s yeast alpha glucosidase, indicating presence of alpha glucosidase inhibitory molecules of diverse polarity and, hence, structures in the T. catappa stem bark extract. This investigation has suggested alpha glucosidase inhibition as a possible action mechanism of the anti-diabetic use of T. catappa, unmasking its stem bark extract as a repertoire for the discovery of compounds of diverse molecular structures with possible anti-diabetic alpha glucosidase inhibitory activities.